Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $116.7 million.

  • Allogene Therapeutics' Cash from Financing Activities rose 376.58% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 74.76%. This contributed to the annual value of $116.7 million for FY2024, which is 21.92% up from last year.
  • Per Allogene Therapeutics' latest filing, its Cash from Financing Activities stood at $116.7 million for FY2024, which was up 21.92% from $95.7 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Cash from Financing Activities peaked at $633.6 million during FY2020, and registered a low of $3.0 million during FY2022.
  • Its 3-year average for Cash from Financing Activities is $71.8 million, with a median of $95.7 million in 2023.
  • In the last 5 years, Allogene Therapeutics' Cash from Financing Activities plummeted by 98.11% in 2021 and then soared by 3,143.90% in 2023.
  • Allogene Therapeutics' Cash from Financing Activities (Yearly) stood at $633.6 million in 2020, then plummeted by 98.11% to $12.0 million in 2021, then slumped by 75.34% to $3.0 million in 2022, then skyrocketed by 3,143.90% to $95.7 million in 2023, then grew by 21.92% to $116.7 million in 2024.